MetaADEDB 2.0 @ LMMD
bivalirudin
(OIRCOABEOLEUMC-GEJPAHFPSA-N)
Structure
SMILES
CC[C@@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(C)C)Cc1ccc(cc1)O)CCC(=O)O)CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](Cc1ccccc1)N)CCCNC(=N)N)CC(=O)N)Cc1ccccc1)CCC(=O)O)CCC(=O)O)C
Type(s)
Approved; Investigational
ATC code(s)
B01AE06
Molecular Formula:
C98H138N24O33
Molecular Weight:
2180.290
Log P:
0.5432
Hydrogen Bond Acceptor:
57
Hydrogen Bond Donor:
28
TPSA:
901.57
CAS Number(s):
128270-60-0; 1191386-55-6
Synonym(s)
1.
bivalirudin
2.
Angiomax
3.
BG 8967
4.
BG-8967
5.
BG8967
6.
Hirulog
7.
Hirulog-1
8.
Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen
9.
Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu
10.
Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64)
External Link(s)
MeSHC074619
PubChem Compound101041682
73952246
16129704
BindingDB50248103
ChEBI59173
CHEMBLCHEMBL2103749
DrugBankDB00006
DrugCentral385
IUPHAR/BPS Guide to PHARMACOLOGY6470
KEGGdr:D03136
Therapeutic Target DatabaseD03ZVY
D09FGS
D0F4HO
D09HVL
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1ThrombosisFAERS: 109
Canada Vigilance: 2

View details

8456428
9125671
14593979
15979436
16893407
19415734
 		CTD
SIDER
Canada Vigilance
US FAERS
2Coagulation time abnormalFAERS: 80
Canada Vigilance: 3		Canada Vigilance
US FAERS
3Thrombosis in deviceFAERS: 79
Canada Vigilance: 2		Canada Vigilance
SIDER
US FAERS
4Stent occlusionFAERS: 52US FAERS
5Procedural complicationFAERS: 46US FAERS
6Drug ineffectiveFAERS: 34
Canada Vigilance: 3		Canada Vigilance
US FAERS
7Chest PainFAERS: 33SIDER
US FAERS
8Myocardial InfarctionFAERS: 33SIDER
US FAERS
9Cardiac ArrestFAERS: 30US FAERS
10Coronary artery perforationFAERS: 30US FAERS
11Cerebrovascular accidentFAERS: 22
Canada Vigilance: 2		Canada Vigilance
US FAERS
12HypotensionFAERS: 21SIDER
US FAERS
13Vascular stent thrombosisFAERS: 19
Canada Vigilance: 3		Canada Vigilance
US FAERS
14Post procedural complicationFAERS: 18US FAERS
15Coagulation time shortenedFAERS: 17US FAERS
16Ventricular FibrillationFAERS: 14
Canada Vigilance: 1		Canada Vigilance
SIDER
US FAERS
17OverdoseFAERS: 13US FAERS
18Cardiac procedure complicationFAERS: 11US FAERS
19Device occlusionFAERS: 11US FAERS
20Product quality issueFAERS: 11US FAERS
21BradycardiaFAERS: 10SIDER
US FAERS
22Iatrogenic injuryFAERS: 9US FAERS
23Reperfusion InjuryFAERS: 9SIDER
US FAERS
24Infusion Site ExtravasationFAERS: 8US FAERS
25Cardiac TamponadeFAERS: 7SIDER
US FAERS
26Medical device complicationFAERS: 7US FAERS
27Wrong technique in drug usage processFAERS: 7US FAERS
28Acute myocardial infarctionFAERS: 5US FAERS
29Drug administration errorFAERS: 5US FAERS
30HypersensitivityFAERS: 5SIDER
US FAERS
31Medication ErrorFAERS: 5US FAERS
32PainFAERS: 5SIDER
US FAERS
33Disease recurrenceFAERS: 4US FAERS
34Drug resistanceFAERS: 4US FAERS
35Electrocardiogram changeFAERS: 4US FAERS
36Embolic strokeFAERS: 4US FAERS
37In-stent arterial restenosisFAERS: 4US FAERS
38Incorrect dose administeredFAERS: 4US FAERS
39Incorrect drug administration rateFAERS: 4US FAERS
40Pharmaceutical product complaintFAERS: 4US FAERS
41AmputationFAERS: 3US FAERS
42Arterial thrombosisFAERS: 3
Canada Vigilance: 1		Canada Vigilance
US FAERS
43Blood creatinine increasedFAERS: 3US FAERS
44Catheter related complicationFAERS: 3US FAERS
45Coagulation test abnormalFAERS: 3US FAERS
46Coronary artery reocclusionFAERS: 3US FAERS
47Ejection Fraction DecreasedFAERS: 3US FAERS
48Endotracheal intubation complicationFAERS: 3US FAERS
49ExtravasationFAERS: 3US FAERS
50Heparin-induced thrombocytopeniaFAERS: 3US FAERS
51OsteomyelitisFAERS: 3US FAERS
52Pericardial effusionFAERS: 3US FAERS
53PneumoniaFAERS: 3US FAERS
54Supraventricular tachycardiaFAERS: 3
Canada Vigilance: 1		Canada Vigilance
US FAERS
55Troponin increasedFAERS: 3
Canada Vigilance: 1		Canada Vigilance
US FAERS
56Unevaluable eventFAERS: 3US FAERS
57Vascular stenosisFAERS: 3US FAERS
58Activated partial thromboplastin time shortenedFAERS: 2US FAERS
59Anaphylactic shockFAERS: 2SIDER
US FAERS
60Angina PectorisFAERS: 2SIDER
US FAERS
61Atrial thrombosisFAERS: 2US FAERS
62Back PainFAERS: 2SIDER
US FAERS
63Cerebral InfarctionFAERS: 2US FAERS
64Coronary artery embolismFAERS: 2US FAERS
65Deep Vein ThrombosisFAERS: 2US FAERS
66Device breakageFAERS: 2US FAERS
67Disease ProgressionFAERS: 2US FAERS
68DisorientationFAERS: 2US FAERS
69Disseminated Intravascular CoagulationFAERS: 2US FAERS
70EmbolismFAERS: 2US FAERS
71EndocarditisFAERS: 2US FAERS
72EpistaxisFAERS: 2SIDER
US FAERS
73ErythemaFAERS: 2US FAERS
74GangreneFAERS: 2US FAERS
75Gastrointestinal arteriovenous malformationFAERS: 2US FAERS
76Gastrointestinal perforationFAERS: 2US FAERS
77HeadacheFAERS: 2SIDER
US FAERS
78Low Cardiac Output SyndromeFAERS: 2US FAERS
79Percutaneous Coronary InterventionFAERS: 2US FAERS
80Procedural hypotensionFAERS: 2US FAERS
81Procedural site reactionFAERS: 2US FAERS
82Product contaminationFAERS: 2US FAERS
83Product measured potency issueFAERS: 2US FAERS
84PruritusFAERS: 2US FAERS
85Puncture site dischargeFAERS: 2US FAERS
86Respiratory FailureFAERS: 2US FAERS
87ShockFAERS: 2SIDER
US FAERS
88TachyarrhythmiaFAERS: 2US FAERS
89TachycardiaFAERS: 2US FAERS
90ThrombocytopeniaFAERS: 216651880
16893407		CTD
SIDER
US FAERS
91Unresponsive to stimuliFAERS: 2US FAERS
92UrticariaFAERS: 2SIDER
US FAERS
93Vascular procedure complicationFAERS: 2US FAERS
94Vessel perforationFAERS: 2US FAERS
95VomitingFAERS: 2SIDER
US FAERS
96Abdominal sepsisFAERS: 1US FAERS
97Accidental exposureFAERS: 1US FAERS
98Accidental overdoseFAERS: 1US FAERS
99Acute kidney injuryFAERS: 1US FAERS
100AgitationFAERS: 1US FAERS
101Alanine Aminotransferase IncreasedFAERS: 1US FAERS
102Alcohol withdrawal syndromeFAERS: 1US FAERS
103Anticoagulation drug level below therapeuticFAERS: 1US FAERS
104AnuriaFAERS: 1US FAERS
105Aortic InjuryFAERS: 1US FAERS
106AphasiaFAERS: 1US FAERS
107Arterial restenosisFAERS: 1US FAERS
108Atrial FibrillationFAERS: 1SIDER
US FAERS
109Atrial FlutterFAERS: 1US FAERS
110Blood creatine phosphokinase increasedFAERS: 1US FAERS
111Blood glucose increasedFAERS: 1US FAERS
112Blood pH decreasedFAERS: 1US FAERS
113Blood potassium decreasedFAERS: 1US FAERS
114Blood urea increasedFAERS: 1US FAERS
115Brain DeathFAERS: 1US FAERS
116BronchospasmFAERS: 1US FAERS
117Burning sensationFAERS: 1US FAERS
118Cardiac DeathFAERS: 1US FAERS
119Cardiac function test abnormalFAERS: 1US FAERS
120CheilitisFAERS: 1US FAERS
121Chest discomfortFAERS: 1US FAERS
122ColitisFAERS: 1US FAERS
123Concomitant disease aggravatedFAERS: 1US FAERS
124Contrast media allergyFAERS: 1US FAERS
125Coronary artery insufficiencyFAERS: 1US FAERS
126Device FailureFAERS: 1US FAERS
127Device computer issueFAERS: 1US FAERS
128Device malfunctionFAERS: 1US FAERS
129DiscomfortFAERS: 1US FAERS
130Disease complicationFAERS: 1US FAERS
131Drug dose omissionFAERS: 1US FAERS
132Drug level below therapeuticFAERS: 1US FAERS
133Drug level increasedFAERS: 1US FAERS
134Drug physiologic incompatibilityFAERS: 1US FAERS
135Dry skinFAERS: 1US FAERS
136Echocardiogram abnormalFAERS: 1US FAERS
137Electrocardiogram ST-T changeFAERS: 1US FAERS
138Electrocardiogram abnormalFAERS: 1US FAERS
139Electromechanical dissociationFAERS: 1US FAERS
140ExsanguinationFAERS: 1US FAERS
141Femoral artery occlusionFAERS: 1US FAERS
142General physical health deteriorationFAERS: 1US FAERS
143General symptomFAERS: 1US FAERS
144Graft infectionFAERS: 1US FAERS
145HemiparesisFAERS: 1US FAERS
146HypoperfusionFAERS: 1US FAERS
147HypoxiaFAERS: 1US FAERS
148In-stent coronary artery restenosisFAERS: 1US FAERS
149IncontinenceFAERS: 1US FAERS
150Incorrect product storageFAERS: 1US FAERS
151Incorrect route of drug administrationFAERS: 1US FAERS
152InfarctionFAERS: 1US FAERS
153Injection site extravasationFAERS: 1US FAERS
154Intestinal infarctionFAERS: 1US FAERS
155Liquid product physical issueFAERS: 1US FAERS
156Mechanical ventilation complicationFAERS: 1US FAERS
157MediastinitisFAERS: 1US FAERS
158Mental status changesFAERS: 1US FAERS
159Myocardial ruptureFAERS: 1US FAERS
160NauseaFAERS: 1SIDER
US FAERS
161NecrosisFAERS: 1US FAERS
162No adverse effectFAERS: 1US FAERS
163No adverse eventFAERS: 1US FAERS
164Non-cardiac chest painFAERS: 1US FAERS
165OnychomycosisFAERS: 1US FAERS
166Peripheral artery dissectionFAERS: 1US FAERS
167Pneumatosis intestinalisFAERS: 1US FAERS
168Post procedural myocardial infarctionFAERS: 1US FAERS
169Post procedural painFAERS: 1US FAERS
170Post procedural strokeFAERS: 1US FAERS
171Product container issueFAERS: 1US FAERS
172Product label confusionFAERS: 1US FAERS
173Product use issueFAERS: 1US FAERS
174Pulmonary EmbolismFAERS: 1US FAERS
175Respiratory arrestFAERS: 1US FAERS
176Septic ShockFAERS: 1US FAERS
177SneezingFAERS: 1US FAERS
178Therapy non-responderFAERS: 1US FAERS
179Vascular Access ComplicationFAERS: 1US FAERS
180Vascular graft thrombosisFAERS: 1US FAERS
181Ventricle ruptureFAERS: 1US FAERS
182Vessel puncture site painFAERS: 1US FAERS
183Vessel puncture site swellingFAERS: 1US FAERS
184White blood cell count decreasedFAERS: 1US FAERS
185Wrong technique in product usage processFAERS: 1
Canada Vigilance: 1		Canada Vigilance
US FAERS
186treatment failureFAERS: 1US FAERS
187Abdominal PainSIDER
188Acute Coronary Syndrome10629409
19804226		CTD
SIDER
189AnxietySIDER
190Arteriovenous fistulaSIDER
191AtelectasisSIDER
192Blood and lymphatic system disordersSIDER
193Carotid Artery Injuries11316950CTD
194Coronary Thrombosis15084542
18036681
18987409		CTD
195Coronary stent thrombosisSIDER
196DermatitisSIDER
197Device related thrombosisCanada Vigilance: 1Canada Vigilance
198DizzinessSIDER
199DyspepsiaSIDER
200Ear and labyrinth disordersSIDER
201EcchymosisSIDER
202Embolism and Thrombosis16084352CTD
203Facial paralysisSIDER
204Feeling abnormalSIDER
205Frank hematuriaSIDER
206Gastrointestinal PainSIDER
207Hemorrhage symptomSIDER
208Hemorrhage

View details

16125490
16598112
18436116
19147609
19281522
19360860
 		CTD
209Increased tendency to bruiseSIDER
210InfectionSIDER
211Inflammation16125490CTD
212Injection Site ReactionSIDER
213Injection site discomfortSIDER
214Injection site painSIDER
215Ischemia18436116CTD
216Major bleedSIDER
217Myocardial Ischemia10562259CTD
218NervousnessSIDER
219OliguriaSIDER
220Pelvic PainSIDER
221PetechiaeSIDER
222PneumothoraxSIDER
223Postoperative HemorrhageSIDER
224Product preparation issueCanada Vigilance: 1Canada Vigilance
225Puncture site reactionSIDER
226SepsisSIDER
227SyncopeSIDER
228TensionSIDER
229Urinary RetentionSIDER
230VIIth nerve paralysisSIDER
231Vascular anomalySIDER
232nervous system disorderSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.